A retrospective study to determine the effect of neo-adjuvant chemotherapy on node positive breast cancer

Do all node positive breast cancer patients require axillary clearance after neo-adjuvant chemotherapy (NAC)? A 4-year retrospective study

International Journal of Surgery ◽

10.1016/j.ijsu.2018.05.053 ◽

2018 ◽

Vol 55 ◽

pp. S17

Author(s):

A. Fitchie ◽

G. Shaaban ◽

N. Redmayne ◽

A. Nagarajakumar ◽

M. Patel ◽

...

Keyword(s):

Breast Cancer ◽

Retrospective Study ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Axillary Clearance ◽

Node Positive ◽

Neo-adjuvant chemotherapy in luminal, node positive breast cancer: characteristics, treatment, and oncological outcomes. A single center’s experience

The Breast ◽

10.1016/s0960-9776(21)00181-8 ◽

2021 ◽

Vol 56 ◽

pp. S54-S55

Author(s):

E. Barbieri ◽

D. Gentile ◽

A. Bottini ◽

W. Gatzemeier ◽

A. Sagona ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Oncological Outcomes ◽

Node Positive ◽

Pathological response in axillary lymph nodes after neo adjuvant chemotherapy in node positive breast cancer

European Journal of Surgical Oncology ◽

10.1016/j.ejso.2020.11.053 ◽

2021 ◽

Vol 47 (1) ◽

pp. e10

Author(s):

Afroza Sharmin ◽

Anupama Nagarajakumar ◽

Azhar Alani ◽

Aliaa Shamardal ◽

Sudeendra Doddi

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Lymph Nodes ◽

Pathological Response ◽

Axillary Lymph Nodes ◽

Axillary Lymph ◽

Node Positive ◽

CT-Guided Wire Localization for Involved Axillary Lymph Nodes After Neo-adjuvant Chemotherapy in Patients With Initially Node-Positive Breast Cancer

The Breast Journal ◽

10.1111/tbj.12597 ◽

2016 ◽

Vol 22 (4) ◽

pp. 390-396 ◽

Cited By ~ 8

Author(s):

Long Trinh ◽

Kanae K. Miyake ◽

Frederick M. Dirbas ◽

Nishita Kothary ◽

Kathleen C. Horst ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Lymph Nodes ◽

Axillary Lymph Nodes ◽

Axillary Lymph ◽

Wire Localization ◽

Ct Guided ◽

Node Positive ◽

593 The Role of Sentinel Node (SLN) Procedure After Neo-adjuvant Chemotherapy (NACT) for Node Positive Breast Cancer (NPBC)

European Journal of Cancer ◽

10.1016/s0959-8049(12)70658-5 ◽

2012 ◽

Vol 48 ◽

pp. S218

Author(s):

Y. Dockx ◽

M.T. Huizing ◽

I. Huyghe ◽

S. Altintas ◽

T. Van den Wyngaert ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Sentinel Node ◽

Node Positive ◽

Neo-Adjuvant Chemotherapy in Luminal, Node Positive Breast Cancer: Characteristics, Treatment and Oncological Outcomes: A Single Center’s Experience

European Journal of Breast Health ◽

10.4274/ejbh.galenos.2021.2021-4-8 ◽

2021 ◽

Vol 17 (4) ◽

pp. 356-362

Author(s):

Erika Barbieri ◽

Damiano Gentile ◽

Alberto Bottini ◽

Andrea Sagona ◽

Wolfgang Gatzemeier ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Oncological Outcomes ◽

Node Positive ◽

Adjuvant chemotherapy for node-positive breast cancer: a retrospective comparison of two different regimens of cyclophosphamide, methotrexate and 5-fluorouracil

The Breast ◽

10.1016/s0960-9776(99)90335-1 ◽

1999 ◽

Vol 8 (1) ◽

pp. 28-34 ◽

Cited By ~ 1

Author(s):

D. Yip ◽

A.M. Rangan ◽

P.R. Harnett ◽

V. Ahern ◽

J. Boyages

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Node Positive ◽

Retrospective Comparison ◽

The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1–3 node positive breast cancer

Cancer Reports ◽

10.1002/cnr2.1546 ◽

2021 ◽

Author(s):

Yogeshkumar Malam ◽

Mohamed Rabie ◽

Konstantinos Geropantas ◽

Susanna Alexander ◽

Simon Pain ◽

...

Keyword(s):

Breast Cancer ◽

Decision Making ◽

Adjuvant Chemotherapy ◽

Oncotype Dx ◽

Node Positive ◽

The Impact ◽

Is three-day steroid medication compulsory to prevent fluid retension in TAC adjuvant chemotherapy for node-positive breast cancer?

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)70573-1 ◽

2008 ◽

Vol 6 (7) ◽

pp. 124-125

Author(s):

Y. Suh ◽

C. Chun ◽

S. Oh ◽

B. Song ◽

S. Jung

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Node Positive ◽

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(09)61523-3 ◽

2009 ◽

Vol 374 (9707) ◽

pp. 2055-2063 ◽

Cited By ~ 163

Author(s):

Kathy S Albain ◽

William E Barlow ◽

Peter M Ravdin ◽

William B Farrar ◽

Gary V Burton ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Node Positive ◽

Randomised Controlled ◽